読み込み中
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
前日終値
$16.03
+$0.57 · +3.69%
日中の時刻はETです。市場データは遅延する場合があります。
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
日中レンジ
現在 $16.03
52週レンジ
現在 $16.03
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
29
割高
センチメント
50
まちまち
リスク
47
やや高いリスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
日中レンジ
現在 $16.03
52週レンジ
現在 $16.03
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 310.7万 USD | — | 373.2万 USD | 264.1万 USD | 82.9万 USD |
| 粗利益 | −310.7万 USD | — | −373.2万 USD | −264.1万 USD | −82.9万 USD |
| 研究開発 | 9285.4万 USD | 1.15億 USD | 1.04億 USD | 1.12億 USD | 7392.2万 USD |
| 販売・一般管理 | 3855.1万 USD | 4172.8万 USD | 3770.4万 USD | 3299.3万 USD | 2261.6万 USD |
| 営業費用 | 1.28億 USD | 1.8億 USD | 1.38億 USD | 2.45億 USD | 1.24億 USD |
| 受取利息 | 1660.7万 USD | 2009.3万 USD | 1671.2万 USD | 490.2万 USD | 19万 USD |
| 支払利息 | — | — | — | 2.01億 USD | — |
| 減価償却費と償却費 | 310.7万 USD | 380.5万 USD | 373.2万 USD | 264.1万 USD | 82.9万 USD |
| 営業利益 | −1.31億 USD | −1.8億 USD | −1.42億 USD | −2.47億 USD | −1.25億 USD |
| 純利益 | −1.25億 USD | −1.62億 USD | −1.25億 USD | −2.43億 USD | −1.23億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.75億0.01%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1.31億1.33%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM9014.64万0.12%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF5620.19万0.06%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO3147.81万0.23%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB2952.49万0.28%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA2375.05万0.11%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO2264.84万0.12%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
